ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2023
The Association Between Sarcopenia and Diabetes: From Pathophysiology Mechanism to Therapeutic Strategy.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 3 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Prevalence and risk factors of sarcopenia in Asian adults with type 2 diabetes: A systematic review and meta-analysis.Journal of diabetes investigation · 2026Pooled it
- Comparative effects of different intensities of aerobic and resistance exercise on glycemic control and cardiorespiratory fitness in middle-aged older patients with type 2 diabetes: a network meta-analysis.Frontiers in public health · 2026Pooled it
- Therapeutic effect of traditional Chinese medicine on diabetic sarcopenia: a systematic review and meta-analysis of preclinical studies.Frontiers in endocrinology · 2025Pooled it
- Sustained and attenuated effects of transitioning from supervised to self-managed resistance training in older adults with type 2 diabetes and sarcopenia: a randomized controlled trial.Acta diabetologica · 2026Trial
- Synergistic effects of synbiotic, protein supplementation, and resistance training on inflammation, oxidative stress, and muscle strength in older adults with type 2 diabetes mellitus: a RCT triple-blinded study.European journal of nutrition · 2026Trial
- Effect of resistance training combined with carbohydrate and protein supplementation on the HOMA-IR, glycemic, lipid profile and hypertrophy of older adults with Type II Diabetes: secondary data analysis of a triple-blind RCT.Aging clinical and experimental research · 2026Trial
- The efficacy of Sarcomeal® oral supplementation plus vitamin D3 on muscle parameters, metabolic factors, and quality of life in diabetic sarcopenia: a randomized controlled clinical trial.Aging clinical and experimental research · 2025Trial
- Biochemical and Molecular Markers Among Prediabetic and Type 2 Diabetes Mellitus Patients.International journal of endocrinology and metabolism · 2026Article
- Shared mechanisms of musculoskeletal dysfunction in type 2 diabetes mellitus: Insights into future therapeutic directions (Review).International journal of molecular medicine · 2026Review
- Effectiveness and Safety of Fixed-Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real-World Study From China.Journal of diabetes · 2026Observational
- Indices of obesity, malnutrition and inflammation are strong predictors of mortality in adults with type 2 diabetes: the FIELD study.Diabetologia · 2026Article
- Association of Smoking and Alcohol Consumption with the Presence of Sarcopenia at Follow-up in Community-Dwelling People Aged 40-74 Years.Annals of geriatric medicine and research · 2026Article
- Sarcopenia in Indian Males Having Clinically Significant Liver Fibrosis in Type 2 Diabetes: A Tertiary-Centre Cross-Sectional Study to Estimate the Prevalence and Associated Factors.Journal of frailty, sarcopenia and falls · 2026Article
- Heterogeneous associations between domain-specific physical activity and sarcopenia risk in diabetic adults: A causal forest analysis.The Journal of international medical research · 2026Article
- Association between GDF-15 and sarcopenia progression in older adults: results from a population-based study.EBioMedicine · 2026Article
- Metabolic-inflammatory axis linking diabetes and sarcopenia: cross-population evidence and explainable ai-based risk modeling.Acta diabetologica · 2026Article
- Bioelectrical phase angle predicts sarcopenia in older adults with type 2 diabetes mellitus.JBMR plus · 2026Article
- Type 1 Diabetes Mellitus as a Model of Body Composition Transformation: Pathogenetic Unity of Combined Phenotypes.International journal of molecular sciences · 2026Review
- Comorbidity Burden Is Associated with Claims-Based Muscle Wasting and Atrophy Suggestive of Possible Sarcopenia in Korean Adults: A Propensity Score-Matched Analysis Using the National Health Insurance Service Database.Healthcare (Basel, Switzerland) · 2026Article
- Dietary protein intake, animal-to-plant protein ratio and risk of sarcopenia in community-dwelling adults: a 9-year follow-up study.Public health nutrition · 2026Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes and sarcopenia are emerging as serious public health issues. Sarcopenia, an age-related disorder characterized by loss of skeletal muscle mass and function, is recognized as a new complication in elderly patients with type 2 diabetes mellitus (T2DM). Type 2 diabetes is characterized by insulin resistance, chronic inflammation, accumulation of advanced glycation products and increased oxidative stress, which can negatively affect skeletal muscle mass, strength and function leading to sarcopenia. There is a mutual interrelationship between T2DM and sarcopenia in light of pathophysiology mechanism and long-term outcome. T2DM will accelerate the decline of muscle mass and function, which will in turn lead to glucose metabolism disorders, reduced physical activity and the risk of diabetes. However, the specific mechanism involved has not been thoroughly studied. Therefore, this review aims to explore the pathophysiology and therapeutic strategy related to sarcopenia and diabetes and provide insight for future investigations, which is of great significance for improving the quality of life in the elderly with diabetes and concurrently reducing the incidence of related complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.